However, when interpreting these results the suppressing effects of hypercalcemia (due to bone metastases) on PTH and the stimulating effects of hypocalcemia due to antiresorptive treatment of bone metastases need to be considered and do likely not allow an evaluation of PTH on survival as an independent marker. The gene discussed is PTH; the disease is Hypercalcemia.